Downloads: 1 | Views: 49 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Research Paper | Pharmacy | United States of America | Volume 8 Issue 7, July 2019 | Rating: 5 / 10
Emergence of New Drug Launch Policies in the United States Managed Care System
Abstract: As several new drugs get approved in the market by regulatory authorities, managed care organizations used to approve them with a prior authorization requirement for immediate coverage while an internal committee makes a final recommendation. However, this landscape has significantly shifted due to dynamics in high cost and highly managed therapeutic areas which have caused impacts to budgets at these organizations. Payers now feel that they would need more time to make a final decision on the newly launched therapy. As a result, there is a greater percentage of organizations that have developed interim policies or new to market policies that place restrictions on these therapies before a final decision is made by the internal committee. From a manufacturer?s perspective, it becomes important to understand and embrace these changes and shifts so that they can proactively begin planning on how they would want to ensure that their patients get access to therapies. Ultimately, manufacturers would want to start well with their launches and meet their access and coverage metrics at the 3-month, 6-month, 9-month timestamps and therefore these shifts become critical for payer marketing teams to monitor, report and take action.
Keywords: managed care, new drug launches, life sciences, commercialization, new to market
Edition: Volume 8 Issue 7, July 2019,
Pages: 1889 - 1890